LLY

1,086.02

+0.46%↑

JNJ

232.42

+0.61%↑

ABBV

215.42

+0.48%↑

UNH

383.37

+1.29%↑

AZN

187.41

-0.42%↓

LLY

1,086.02

+0.46%↑

JNJ

232.42

+0.61%↑

ABBV

215.42

+0.48%↑

UNH

383.37

+1.29%↑

AZN

187.41

-0.42%↓

LLY

1,086.02

+0.46%↑

JNJ

232.42

+0.61%↑

ABBV

215.42

+0.48%↑

UNH

383.37

+1.29%↑

AZN

187.41

-0.42%↓

LLY

1,086.02

+0.46%↑

JNJ

232.42

+0.61%↑

ABBV

215.42

+0.48%↑

UNH

383.37

+1.29%↑

AZN

187.41

-0.42%↓

LLY

1,086.02

+0.46%↑

JNJ

232.42

+0.61%↑

ABBV

215.42

+0.48%↑

UNH

383.37

+1.29%↑

AZN

187.41

-0.42%↓

Accueil・Liste d'Actions・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Fermé

SecteurSoins de santé

2.18 7.39

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.05

Max

2.13

Chiffres clés
By Trading Economics
Revenu	-3.8M -43M
BPA	-0.18
Employés	150
EBITDA	-3.9M -43M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+335.5% upside

Dividendes
By Dow Jones
Prochains Résultats	12 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-96M 690M
Ouverture précédente	-5.21
Clôture précédente	2.18

Sentiment de l'Actualité

By Acuity

50%

154 / 344 Classement par Healthcare

Allogene Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

26 mai 2026, 16:52 UTC

Principaux Événements d'Actualité

NYMEX Overview: Brent Crude Futures Up; Iran Warns of Retaliation After US Strike -- OPIS

26 mai 2026, 23:57 UTC

Résultats

Sociedad Quimica 1Q Rev $1.76B >SQM

26 mai 2026, 23:57 UTC

Résultats

Sociedad Quimica 1Q EPS $1.28 >SQM

26 mai 2026, 23:48 UTC

Market Talk

Nikkei May Rise on Continued AI Enthusiasm -- Market Talk

26 mai 2026, 21:54 UTC

Résultats

Webco Industries 3Q EPS $11.61 >WEBC

26 mai 2026, 21:54 UTC

Résultats

Webco Industries 3Q Sales $179.6M >WEBC

26 mai 2026, 21:48 UTC

Market Talk

GE Aerospace's Repair Boom Should Last for Years -- Market Talk

26 mai 2026, 21:00 UTC

Market Talk

ESG Roundup: Market Talk

26 mai 2026, 20:58 UTC

Acquisitions, Fusions, Rachats

Uber's $11.6 Billion Bid for DoorDash Rival Is About Future Proofing It From Robots -- Barrons.com

26 mai 2026, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 mai 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

26 mai 2026, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

26 mai 2026, 19:22 UTC

Market Talk

Cryptocurrencies Add to Losses in Afternoon Trading -- Market Talk

26 mai 2026, 19:17 UTC

Market Talk

Oil Recovers Some Losses on U.S.-Iran Skirmishes -- Market Talk

26 mai 2026, 18:56 UTC

Market Talk

U.S. Natural Gas Futures Slip in Rangebound Trading -- Market Talk

26 mai 2026, 18:03 UTC

Market Talk

AutoCanada Faces Soft Demand, Slow Normalization -- Market Talk

26 mai 2026, 17:42 UTC

Market Talk

Grains Await Fresh Trading Catalyst -- Market Talk

26 mai 2026, 17:33 UTC

Market Talk

Salesforce, Snowflake Could Dispel Software Bear Thesis -- Market Talk

26 mai 2026, 17:21 UTC

Market Talk

Canada Faces a Labor Market Squeeze -- Market Talk

26 mai 2026, 16:52 UTC

Market Talk

Bonds to Fund Infrastructure for Data Centers Could Be Risky -- Market Talk

26 mai 2026, 16:43 UTC

Market Talk

Spotify's Latest Audio Play: Magazine Articles -- Market Talk

26 mai 2026, 16:24 UTC

Market Talk

Dollarama's LATAM Slowdown, Australia Costs Seen as Transient -- Market Talk

26 mai 2026, 16:21 UTC

Market Talk

Oil Extends Gains As Strikes Add Tension to U.S.-Iran Talks -- Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Energy & Utilities Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

26 mai 2026, 16:20 UTC

Market Talk

Acquisitions, Fusions, Rachats

Auto & Transport Roundup: Market Talk

26 mai 2026, 16:16 UTC

Market Talk

Alberta Separation Threat Poses Headwind for Canada Dollar -- Market Talk

26 mai 2026, 16:01 UTC

Market Talk

Bitcoin Lower as Stress Builds for Holders -- Market Talk

26 mai 2026, 15:21 UTC

Market Talk

Hyperliquid Pushes Up to New All-Time High -- Market Talk

Comparaison

Variation de prix

Allogene Therapeutics Inc prévision

Objectif de Prix

By TipRanks

335.5% hausse

Prévisions sur 12 Mois

Moyen 8.71 USD 335.5%

Haut 14 USD

Bas 3.85 USD

Basé sur 14 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

14 ratings

Achat

Maintien

Vente

Basé sur 14 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

154 / 344Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.